Clinicopathologic characteristics of primary HHV8-negative EBL compared with clinical series of PEL
| Characteristic . | Primary HHV8-negative EBL (current study), n = 64 . | PEL65-67 . |
|---|---|---|
| HHV8 status | Negative | Positive |
| HIV infection | Negative | Positive |
| Median age, y | 77 | 4466 |
| Male | 63% | >95%66 |
| Site of involvement | Single site (59%) | Single site |
| Multiple sites (41%) | ||
| Extracavitary involvement | No | Some |
| Pan B-cell markers (CD19, CD20, CD79a) | Positive | Negative |
| Plasma cell–related markers (CD138) | Usually negative (CD138 positive; 12%) | Positive |
| Prognosis | Favorable | Poor |
| (2-y OS 84.7%) | (1-y OS 30%67 ) |
| Characteristic . | Primary HHV8-negative EBL (current study), n = 64 . | PEL65-67 . |
|---|---|---|
| HHV8 status | Negative | Positive |
| HIV infection | Negative | Positive |
| Median age, y | 77 | 4466 |
| Male | 63% | >95%66 |
| Site of involvement | Single site (59%) | Single site |
| Multiple sites (41%) | ||
| Extracavitary involvement | No | Some |
| Pan B-cell markers (CD19, CD20, CD79a) | Positive | Negative |
| Plasma cell–related markers (CD138) | Usually negative (CD138 positive; 12%) | Positive |
| Prognosis | Favorable | Poor |
| (2-y OS 84.7%) | (1-y OS 30%67 ) |